Adipocytes play a central role in whole-body energy homoeostasis. Complex regulatory transcriptional networks control adipogensis, with ligand-dependent activation of PPARγ (peroxisome proliferator-activated receptor γ ) being a decisive factor. Yet the identity of endogenous ligands promoting adipocyte differentiation has not been established. Here we present a critical evaluation of the role of LOXs (lipoxygenases) during adipocyte differentiation of 3T3-L1 cells. We show that adipocyte differentiation of 3T3-L1 preadipocytes is inhibited by the general LOX inhibitor NDGA (nordihydroguaiaretic acid) and the 12/15-LOX selective inhibitor baicalein. Baicalein-mediated inhibition of adipocyte differentiation was rescued by administration of rosiglitazone. Treatment with baicalein during the first 4 days of the differentiation process prevented adipocyte differentiation; supplementation with rosiglitazone during the same period was sufficient to rescue adipogenesis. Accordingly, we demonstrate that adipogenic conversion of 3T3-L1 cells requires PPARγ ligands only during the first 4 days of the differentiation process. We show that the baicalein-sensitive synthesis of endogenous PPARγ ligand(s) increases rapidly upon induction of differentiation and reaches a maximum on days 3-4 of the adipocyte differentiation programme. The conventional platelet-and leucocyte-type 12(S)-LOXs and the novel eLOX-3 (epidermistype LOX-3) are expressed in white and brown adipose tissue, whereas only eLOX-3 is clearly expressed in 3T3-L1 cells. We suggest that endogenous PPARγ ligand(s) promoting adipocyte differentiation are generated via a baicalein-sensitive pathway involving the novel eLOX-3.
INTRODUCTION
Differentiation of 3T3-L1 preadipocytes into adipocytes depends on an exogenous supply of fatty acids, and growth in delipidated serum prevents adipocyte differentiation unless the medium is supplemented with PPAR (peroxisome proliferator-activated receptor) agonists [1] . Fatty acids activate all three members of the PPAR family in the micromolar range [2] [3] [4] [5] , whereas several fatty acid metabolites exhibit a more subtype-selective pattern of activation in the nanomolar range [2, 3] . Adipocyte differentiation of preadipocytes is strictly dependent on PPARγ [6] [7] [8] , and forced expression of PPARγ and/or administration of potent PPARγ agonists promote adipose conversion of fibroblasts and myoblasts [9, 10] . The first natural high-affinity PPARγ ligand to be identified was a prostaglandin J 2 derivative [11] , and several prostaglandin derivatives induce adipocyte differentiation of preadipocytes [11, 12] . The role of COXs (cyclo-oxygenases) in adipocyte differentiation has been a matter of dispute [13] , but the finding that some of the commonly used COX inhibitors are PPARγ agonists explains, at least in part, why conflicting results were obtained [14, 15] , and different
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classes of prostaglandins exert opposing effects on adipocyte differentiation. Thus prostaglandin I 2 has been reported to promote adipocyte differentiation [16, 17] , whereas prostaglandin F 2α inhibits differentiation via a p42/p44 MAPK (mitogen-activated protein kinase)-mediated phosphorylation and inactivation of PPARγ [18] . The LOXs (lipoxygenases) produce mainly leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid, and hydroxyoctadecaenoic acids from linoleic acid. LOX metabolites activate PPARγ [2, [19] [20] [21] [22] and, therefore, LOX-generated products have the potential to induce adipogenesis [2] . Surprisingly little is known about the expression and function of LOXs in preadipocytes and adipocytes, and, as in the case of COXs, conflicting results have been presented. LOX inhibitors were reported to be without effect on the differentiation of primary adipocyte precursors [23] and 1246 cells [24] , whereas Shillabeer et al. [25] demonstrated that the general LOX inhibitor NDGA (nordihydroguaiaretic acid) inhibited the hormonally induced differentiation of primary rat adipocytes. Recently it was also reported that the ability of arachidonic acid to stimulate glucose uptake in mature 3T3-L1 cells was blocked by NDGA [26] .
To investigate the specific role of LOXs in adipocyte differentiation, we critically examined the effects of known LOX inhibitors on the differentiation of 3T3-L1 cells. Our results demonstrate that inhibition of the LOX pathway, but not the COX or the cytochrome P450 epoxygenase pathways, prevents adipocyte differentiation of 3T3-L1 cells. Of note, inhibition of adipocyte differentiation by LOX inhibitors is rescued by the administration of the PPARγ agonist rosiglitazone. We demonstrate that platelet (p)-type 12(S)-LOX, leucocyte (l)-type 12(S)-LOX and epidermis (e)-type LOX-3 are expressed in WAT (white adipose tissue) and BAT (brown adipose tissue), whereas only eLOX-3 is clearly detectable at the mRNA level in 3T3-L1 preadipocytes and adipocytes. Our findings suggest that PPARγ ligands necessary for adipocyte differentiation are generated via a LOX-dependent pathway, and that the novel eLOX-3 might play an important role in the production of adipose-conversion-promoting PPARγ agonists. Differentiating preadipocytes are only sensitive to LOX inhibitors during the first 4 days of differentiation, and PPARγ agonists are only needed during the same period to induce adipocyte differentiation. In keeping with this finding, we demonstrate that the accumulation of endogenous PPARγ agonist(s) increases rapidly upon induction of differentiation, reaching a maximum on day 3-4 of the differentiation programme.
EXPERIMENTAL

Cell culture and differentiation
3T3-L1 cells were cultured to confluence in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % (v/v) calf serum. At 2 days post-confluence (designated day 0), cells were induced to differentiate with DMEM supplemented with 10 % (v/v) FBS (fetal bovine serum), 1 µM dexamethasone (Sigma), 0.5 mM isobutylmethylxanthine (Sigma), 1 µg/ml insulin (Novo Nordisk A/S) and ligands/inhibitors dissolved in DMSO. Cells not treated with ligands/inhibitors received similar volumes of DMSO. After 48 h, the media were replaced with DMEM supplemented with 10 % FBS and 1 µg/ml insulin. The cells were subsequently re-fed every 48 h with DMEM supplemented with 10 % FBS.
Isolation of the stromal vascular fraction and adipocytes from mice
The stromal vascular fraction and adipocytes were obtained from 8-week-old C57BL/6J mice. Freshly dissected epididymal and interscapular fat depots (WAT and BAT respectively) were rapidly excised and washed in PBS, then minced and digested for 40 min at 37
• C with 2 mg/ml collagenase A (Roche) in the presence of 20 mg/ml BSA (Sigma) in DMEM under mild controlled agitation. After digestion, 2 vol. of DMEM supplemented with 10 % FBS was added to the tissue remnants. Adipocytes were separated from stromal vascular cells by filtration (250 and 25 µm nylon filters) and centrifugation as described previously [27, 28] . Contaminating erythrocytes were eliminated from the stromal vascular fraction by a wash with sterile distilled water. Total RNA was extracted from the two fractions using TriReagent TM kit (Euromedex) according to the manufacturer's instructions. Animals were killed by cervical dislocation. All experimental protocols were performed in accordance with the recommendations of the French Accreditation of Laboratory Animal Care.
Oil Red O staining
Dishes were washed in PBS, and the cells were fixed in 3.7 % (w/v) formaldehyde for 1 h and stained with Oil Red O as described previously [29] .
Multiplex RT-PCR (reverse transcription-PCR)
RNA purification, reverse transcription and multiplex RT-PCR were performed as described previously [29] . Primers (upstream and downstream respectively), the number of cycles used and the sizes of the amplified fragment were: mouse aP2 (adipocyte lipidbinding protein), 5 -GAACCTGGAAGCTTGTCGCC-3 and 5 -ACCAGCTTGTCACCATCTCG-3 (14 cycles, 
Real time RT-PCR
Total RNA was purified as described [29] . Reverse transcriptions were performed in 25 µl reactions containing Invitrogen 1 st Strand Buffer, 6 µM oligo(dT) (Applied Biosystems), 10 mM dithiothreitol, 40 units of RNAguard (Amersham Pharmacia Biotech), 0.9 mM of each dNTP (Amersham Pharmacia Biotech), 1 µg of total RNA and 200 units of Moloney murine leukaemia virus reverse transcriptase (Invitrogen). Reactions were left for 10 min at room temperature, followed by incubation at 37
• C for 1 h. After cDNA synthesis, reactions were diluted with 50 µl of water and frozen at − 80
• C. PCR was performed in 25 µl reactions containing SYBR Green Mastermix (Applied Biosystems), 1.5 µl of diluted cDNA and 300 nM of each primer. Reaction mixtures were preheated at 95
• C for 10 min. Denaturation was followed by 40 cycles of melting at 95
• C for 15 s, annealing at 60
• C for 30 s, elongation at 72
• C for 60 s (ramp 45 s between 72 • C and 78 • C) and measurements at 78
• C for 30 s. All reactions contained the TBP primer set as an internal standard. Primers (upstream and downstream) were: eLOX-3, 5 -AGTGGGCAGCATGACTTT-3 and 5 -GAAGGCTGCGATGCTCT-3 ; l12-LOX, 5 -TCA-TGAATCGGTACGTGG-3 and 5 -GTCGCGTCCTTGGTTT-3 ; p12-LOX, 5 -CCAGACATGGTACCTCTA-3 and 5 -CAGTCCT-AGGGCTGAC-3 ; TBP, 5 -ACCCTTCACCAATGACTCCTATG-3 and 5 -ATGATGACGGCAGCAAATCGC-3 .
Whole cell extracts and Western blot analysis
Whole cell extracts, electrophoresis, blotting, visualization and stripping of membranes were performed as described [29] . Primary antibodies used were rabbit anti-(p42/p44 MAPK) antibodies and mouse anti-[phospho-p42/p44 MAPK (Thr-202/ Tyr-204)] antibodies (Cell Signaling Technology), and rabbit antivimentin antibodies (DAKO). A rabbit polyclonal anti-peptide antibody was raised against a peptide corresponding to 23 amino acids (167-189) of the unique extra subdomain of eLOX-3. This antibody specifically recognizes recombinant eLOX-3 and does not show cross-reactivity with any other LOX isoenzymes (P. Krieg, unpublished work).
Secondary antibodies were horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies obtained from DAKO.
DNA quantification
Cell samples were harvested by trypsinization and dissolved in high-salt harvest buffer as described previously [30] . DNA amounts were measured on a Hoefer DyNA Quant 200 instrument after addition of Hoechst 33 258 [30] .
De novo fatty acid synthesis
Cells were incubated with [1(2)- 14 C]acetic acid, sodium salt (0.2 µCi/ml medium) (Amersham Pharmacia Biotech) for 4 h, harvested in water and frozen. Fatty acids were extracted according to the procedure of Folch, Lees and Sloane-Stanley [31] with minor modifications. Cells sonicated in 0.5 ml of water were added dropwise to 2.5 ml of methanol with constant shaking, and 1.25 ml of chloroform was then added. After shaking (300 rev./ min, 5 min) and centrifugation (2000 g, 5 min), the pellet was dissolved in 2.5 ml of methanol and 3.75 ml of chloroform. After a second shaking (300 rev./min, 5 min) and centrifugation (2000 g, 5 min) the supernatants were collected, and 4 ml of water was added. Separation was allowed overnight at − 20
• C. After centrifugation (2000 g, 5 min) at room temperature, the upper phase was removed and the lower phase was dried under N 2 at 35
• C. The lipids were hydrolysed in 2 ml of 0.5 M KOH in ethanol/water (9:1, v/v) for 60 min at 80
• C, followed by acidification by 0.35 ml of 4 M HCl. The fatty acids were extracted twice with 3 ml of hexane, dried under N 2 at 35
• C, dissolved in 8 ml of scintillation liquid and quantified by scintillation counting.
Cellular levels of triacylglycerols
Cells grown in six-well plates were harvested in 1 ml of water and frozen. The cells were sonicated and the cellular levels of triacylglycerols were measured on an AXON Byer spectrophotometer using the TRINDER reaction kit from bioMèrieux.
Plasmids and tranfections
The UASx4-TK-luc reporter [32] (where UAS is upstream activator sequence), containing four Gal4-responsive elements, was kindly provided by Ronald M. Evans (Howard Hughes Medical Institute, La Jolla, CA, U.S.A.). The plasmid pcDNA1-GAL4-PPARγ (LBD), encoding the Gal4-DBD-PPARγ -LBD fusion protein [i.e. the DBD (DNA-binding domain) of Gal4 fused to the LBD (ligand-binding domain) of PPARγ ] has been described [33] . The CMV-β-galactosidase plasmid (where CMV is cytomegalovirus) used for normalization is from Clontech. NIH-3T3 cells (50 % confluent) in 12-well dishes were transiently transfected by the calcium phosphate method. For each well, 500 ng of UASx4-TK-luc reporter, 50 ng of Gal4-DBD-PPARγ -LBD and 25 ng of CMV-β-galactosidase were used. At 5 h after transfection, the medium was changed and cells were incubated for 20 h with rosiglitazone, baicalein or the DMSO vehicle as indicated. Cells were analysed for luciferase and β-galactosidase activities by standard procedures. 3T3-L1 cells (70 % confluent) in 15 cm dishes were transfected by the calcium phosphate method. Each dish was transfected with 40 µg of UASx4-TKluc reporter, 800 ng of Gal4-DBD-PPARγ -LBD and 800 ng of CMV-β-galactosidase. At 5 h after transfection the cells were split into 12-well dishes and subjected to standard differentiation procedures as described above. The cells were differentiated in the presence of baicalein or the DMSO vehicle, harvested at the time points indicated and analysed for luciferase and β-galactosidase activities by standard procedures.
Scintillation proximity assay
The hPPARγ -binding assay was performed as described by Nichols et al. [34] , with minor modifications as described by Ebdrup et al. [35] . Briefly, the ligand binding displacement assay is based on biotinylated purified PPARγ -LBD (amino acids C 165 to Stop) bound to scintillation proximity assay particles. Ragaglitazar (K d 85 nM) was labelled with 3 H and used as tracer for the receptor GST-PPARγ -LBD (where GST is glutathione S-transferase). 
Statistical analyses and presentation of data
All experiments were performed in duplicate or triplicate and repeated two to five times. The data presented in bars represent means + − S.D. of triplicate measurements in a representative experiment. Where relevant, a two-tailed Student's t test was applied for equality of means at the significance level of P < 0.05.
RESULTS
Inhibition of LOXs prevents the adipocyte differentiation of 3T3-L1 cells
To examine the role of LOXs and cytochrome P450 epoxygenases in adipocyte differentiation, we induced 3T3-L1 cells to differentiate by a standard differentiation protocol including MDI [isobutylmethylxanthine ('methylisobutylxanthine'), dexamethasone and insulin] in the absence or presence of selected inhibitors of eicosanoid synthesis. Differentiation was assessed by staining of lipids with Oil Red O at day 10 ( Figure 1A ). For comparison we also included the COX inhibitor indomethacin. Several COX inhibitors, including indomethacin, are also PPARγ agonists, with reported EC 50 values in the micromolar range [14, 15] . In our cell system, indomethacin at 1 µM did not enhance PPARγ -dependent transactivation, whereas a slight enhancement was observed at 10 µM (results not shown). Figure 1 shows that indomethacin at 1 and 10 µM, as expected, did not affect the MDI-induced differentiation of 3T3-L1 cells. Similarly, inhibition of cytochrome P450 expoxygense by 17-octadecynoic acid had no effect on the MDI-induced differentiation of 3T3-L1 cells (Figure 1) . However, the general LOX inhibitor NDGA completely prevented the MDI-induced accumulation of lipid, and the cells remained fibroblast-like ( Figure 1A ). Multiplex RT-PCR confirmed that inhibition of LOX activity prevented expression of adipocyte-specific markers ( Figure 1B) . Baicalein, a well-known inhibitor of 12/15-LOX, prevented the MDI-induced accumulation of lipid ( Figure 1A) , as well as the expression of adipocyte differentiation markers ( Figure 1B ) and the induction of de novo fatty acid synthesis ( Figure 1C) . A dose-response study demonstrated that a concentration of baicalein between 10 and 20 µM was sufficient to inhibit adipocyte differentiation (Figure 2) . This concentration is comparable with the concentrations used to inhibit 12/15-LOX activity in other cell types [36, 37] . 
Rosiglitazone rescues the adipocyte differentiation of baicalein-treated cells
Since several LOX products have been shown to activate PPARγ -mediated transactivation, we examined the obvious possibility that baicalein inhibited adipocyte differentiation by preventing the synthesis of endogenous PPARγ agonists. If so, we hypothesized that addition of a synthetic PPARγ agonist would rescue the adipocyte differentiation of baicalein-treated cells. Figure 3 clearly demonstrates that administration of rosiglitazone completely rescued the adipocyte differentiation of 3T3-L1 cells in the presence of baicalein. In the absence of added rosiglitazone, the baicalein-treated cells remained fibroblast-like, but when rosiglitazone was included, the cells rounded up and accumulated triacylglycerols ( Figure 3A) . RT-PCR analysis revealed that the cells expressed adipocyte marker genes ( Figure 3B) , and the cells also synthesized fatty acids at a rate similar to control cells treated with standard inducers only ( Figure 3C ).
Baicalein does not inhibit the binding of ligands to or the ligand-dependent activation of PPARγ
NDGA and other LOX inhibitors (quercetin and morin) were recently reported to bind directly to the PPARs, and to diminish ligand-induced PPARα-and PPARγ -mediated transactivation [38] . Therefore we investigated whether baicalein decreased ligand-induced PPARγ -mediated transactivation. 3T3-L1 cells were transfected with a vector expressing Gal4-PPARγ (LBD) and a luciferase reporter construct, as described in the Experimental section. In the first set of experiments we investigated whether 20 µM baicalein decreased the dose-dependent induction of PPARγ -mediated transactivation by rosiglitazone. In the second set of experiments we investigated whether increasing concentrations of baicalein decreased the rosiglitazone-induced activation of PPARγ -mediated transactivation. Figure 4 (A) shows that 20 µM baicalein alone enhanced PPARγ -mediated transactivation almost 2-fold, and did not prevent the dosedependent increase induced by rosiglitazone. Similarly, 20 µM baicalein did not prevent a dose-dependent induction of PPARγ -mediated transactivation by the natural LOX product 15(S)-hydroxyeicosatetraenoic acid (results not shown). Figure 4(B) shows that the ability of 500 nM rosiglitazone to enhance PPARγ -mediated transactivation was not impaired by the addition of increasing concentrations of baicalein; just the opposite, in fact, as addition of baicalein increased PPARγ -mediated transactivation further. The above findings suggested either that baicalain interacted directly with the LBD of PPARγ to enhance transactivation or that addition of baicalein increased PPARγ -dependent transactivation indirectly. To answer this question we used a scintillation proximity assay to test the ability of baicalein to displace ragaglitazar from the LBD of PPARγ . Figure 4 (C) demonstrates that baicalein up to a concentration of 20 µM did not displace ragaglitazar. At higher concentrations the colouring by baicalein in solution interfered with the read-out of the measurements, and this may also explain the slight apparent displacement observed at 20 µM. We conclude that baicalein at most is a very-low-affinity PPARγ ligand, and that the presence of baicalein does not impair the ligand-dependent induction of PPARγ -mediated transactivation.
Baicalein-dependent inhibition of adipocyte differentiation is executed during the early stages of the differentiation process
A number of observations indicate that processes occurring during the first 2-4 days after stimulation with adipogenic inducers are crucial for adipocyte differentiation [39] [40] [41] [42] . To determine the period during which 3T3-L1 cells were sensitive to baicaleinmediated inhibition of differentiation, we treated cells with baicalein for different periods during the differentiation process. Differentiation was assessed by staining of lipids with Oil Red O, RT-PCR analysis of marker genes and measurements of triacylglycerols at day 10.
To prevent differentiation of 3T3-L1 cells completely, baicalein was necessary from day 0, the time when differentiation was induced ( Figure 5 ). The inhibitory effect of baicalein was far less pronounced when added on day 2, and abolished when added on day 4 or later ( Figure 5) . Interestingly, the presence of baicalein during the first 4 days was sufficient to prevent adipocyte differentiation, and even treatment limited to the period from day 0 to day 2 resulted in a significant inhibition of adipocyte differentiation ( Figures 6A-6C ).
Since addition of rosiglitazone on day 0 rescued the differentiation of baicalein-treated cells, and baicalein was only needed in the period between days 0 and 4 to prevent differentiation, we hypothesized that rosiglitazone would be necessary only during the first 4 days in order to rescue adipocyte differentiation in the presence of baicalein. Therefore 3T3-L1 cells were induced with MDI in the presence of 20 µM baicalein with and without 0.5 µM rosiglitazone. Baicalein was present during the entire differentiation period, whereas rosiglitazone was withdrawn at different time points as indicated. Figure 6(D) shows that administration of rosiglitazone from day 0 to day 4 rescued adipogenesis, and even when rosiglitazone was withdrawn on day 2, substantial differentiation and accumulation of triacylglycerols occurred (Figures 6D-6E ).
Endogenous PPARγ ligands accumulate during the early stages of adipocyte differentiation
The finding that addition of rosiglitazone from day 0 to day 4 rescues baicalein-dependent inhibition of adipogenesis suggested that endogenous PPAR ligands might be synthesized by a baicalein-sensitive pathway during the first days of adipogenesis. To test this hypothesis, preconfluent 3T3-L1 cells were transfected with a UASx4-TK-luc reporter plasmid, a Gal4-DBD-PPARγ -LBD expression plasmid and a CMV-β-galactosidase normalization vector. The cells were subsequently grown to confluence and induced to differentiate using the MDI protocol in the presence or absence of 20 µM baicalein. Cells were harvested at the time of induction, and after 0.5, 1, 2, 3, 4, 6 and 8 days. At each time point luciferase activity was measured and normalized to β-galactosidase activity. Figure 7(A) demonstrates that the normalized luciferase activity increased approx. 3-fold during the first 3-4 days of the differentiation process, indicating enhanced production of endogenous PPARγ ligands during this period. In the presence of baicalein, no differentiation occurred, and hence no differentiation-dependent enhancement of reporter activity was observed (results not shown). To illustrate the baicalein-sensitive production of endogenous PPARγ ligands, we calculated the ratio between the normalized luciferase activity in the absence and in the presence of baicalein. This ratio represents the baicalein-sensitive accumulation of PPARγ agonists at each time point. Figure 7 (B) clearly shows that the baicalein-sensitive accumulation of PPARγ agonists increased rapidly upon induction of differentiation, reaching a maximum around days 3-4 and then declining. Thus the baicalein-sensitive accumulation of PPARγ agonists occurring during the first 4 days of the differentiation process very closely mirrors the induction of PPARγ 2 expression. Of note, this period coincides with the period of sensitivity to baicalein and the period during which addition of a synthetic PPARγ agonist is needed to overcome the baicaleindependent inhibition of adipocyte differentiation.
Differential expression of LOXs in WAT, BAT and 3T3-L1 cells
A comprehensive analysis of the expression of the different LOXs in adipose tissue has not yet been reported. In mice, seven different LOX types have been identified, and consequently we designed specific primer sets for all known LOXs in the mouse, and used conventional RT-PCR as well as real-time RT-PCR analyses to study the expression of different LOXs in the stromal vascular fraction and adipocytes from mouse WAT and BAT respectively. These analyses revealed that p12(S)-LOX and l12(S)-LOX, and the novel eLOX-3, were expressed in both the stromal vascular fraction and adipocytes isolated from BAT and WAT ( Figure 8A ). Generally, expression of these LOXs was higher in the stromal vascular fraction than in adipocytes. Interestingly, expression of p12(S)-LOX was higher in BAT than WAT, whereas the reverse expression pattern was observed for l12(S)-LOX and eLOX-3 ( Figure 8B) .
Expression of 5(S)-LOX, 8(S)-LOX, 12(S)-LOX and 12(R)-LOX could not be detected in either WAT nor BAT (results not shown).
To investigate the expression of LOXs during the differentiation of 3T3-L1 cells, RNA was isolated at different time points as indicated, and expression of the different LOXs was determined by real-time RT-PCR. Surprisingly, only the novel eLOX-3 was clearly detected, and, even more unexpectedly, expression of eLOX-3 mRNA declined precipitously upon induction of differentiation ( Figure 9A ). Considering that 3T3-L1 differentiation seemed to be dependent on LOX activity, the drastic decline in eLOX-3 mRNA expression was surprising. However, Western blot analyses revealed that the level of eLOX-3 protein was maintained during the critical first 4 days of the differentiation process, suggesting post-transcriptional control of eLOX-3 protein accumulation in this period ( Figure 9B ).
DISCUSSION
The importance of PPARγ in adipocyte differentiation is well recognized [6, 9, 10, 43] ; in addition, a supply of exogenous fatty acids is required for adipocyte differentiation unless synthetic PPAR agonists are included in the medium [1] . Several adipogenic factors are secreted from adipocytes [44] and, accordingly, media conditioned by adipocytes efficiently induce adipocyte differentiation [45] . Interestingly, it was shown that forced expression of ADD-1 in 3T3-L1 cells promoted differentiation and enhanced the production and secretion of lipid molecule(s) that specifically bound to and activated PPARγ [45] .
Several metabolites from the COX and LOX pathways activate PPARγ in the nanomolar range [2, 3, 11, [19] [20] [21] , but it is not yet known whether one of the known activators represents a biologically functional endogenous ligand in the context of adipocyte differentiation. The results presented in this paper now demonstrate that a NDGA-and baicalein-sensitive pathway is essential for the differentiation of 3T3-L1 cells, and that the requirement for LOX activity is confined to the initial 4 days of the differentiation process. During this period a transient activation of the ERK1 (extracellular-signal-regulated kinase 1) and ERK2 MAPKs occurs, and the preadipocytes re-enter the cell cycle and undergo a process known as mitotic clonal expansion [13] . It has been a matter of dispute whether this is a prerequisite for differentiation [46] [47] [48] . However, several lines of evidence now suggest that mitotic clonal expansion is an integral part of the differentiation process [49, 50] and that transient up-regulation of p42/p44 MAPK (ERK1 and ERK2) activity, which is required for mitotic clonal expansion, promotes adipogenesis [51] . Different LOX metabolites are known to influence the MAPK signalling pathway, and LOX inhibitors have been shown to reduce the growth of different cell lines [52] [53] [54] . A priori it remained a possibility that both processes might be affected by treatment with LOX inhibitors. However, the profile of MAPK activation was unaffected by baicalein, and only a modest reduction in mitotic clonal expansion was observed in the cells treated with baicalein, and this was not accompanied by an impaired ability of rosiglitazone to rescue differentiation ( Figure 3 and results not shown). Thus we conclude that the LOX-inhibitor-dependent inhibition of adipocyte differentiation is not caused by an aberrant regulation of MAPK activation or mitotic clonal expansion. Rather, our results suggest that endogenous PPARγ ligand(s) promoting adipocyte differentiation is/are generated via a pathway that involves one or more LOXs, since administration of the synthetic PPARγ agonist rosiglitazone rescued the differentiation of preadipocytes treated with LOX inhibitors. This suggestion is underscored by the previous finding that induction of the differentiation of primary rat preadipocytes with medium conditioned by mature adipocytes is insensitive to NDGA, whereas NDGA prevented adipogenic conversion induced by MDI [25] . However, we cannot exclude the possibility that LOX activity is required for induction of PPARγ 2 expression itself, and that the rescue of differentiation of baicalein-treated cells by rosiglitazone involves a feed-forward type up-regulation of PPARγ 2 expression.
A comprehensive analysis by RT-PCR revealed that p12(S)-LOX and l12(S)-LOX, and the novel eLOX-3, were expressed in BAT and WAT. At the RNA level, higher levels of expression were detected in the stromal vascular fraction than in adipocytes. Of note, eLOX-3 and l12(S)-LOX were more abundantly expressed in WAT than in BAT, whereas expression of p12(S)-LOX was significantly higher in BAT than in WAT. Unexpectedly, only eLOX-3 was clearly detected in 3T3-L1 cells. Very low levels of the conventional LOXs were detectable, but, at least at the mRNA level, expression of the conventional LOXs appeared to be orders of magnitude lower than expression of eLOX-3. Surprisingly, expression of eLOX-3 mRNA declined rapidly upon induction of differentiation. However, the level of the eLOX-3 protein remained constant during the first 4 days of differentiation, indicating a pronounced post-transcriptional regulation of eLOX-3 expression.
In mice, l12(S)-LOX and e12(S)-LOX belong to the group of 12/15(S)-LOXs. Products generated by 12/15-LOXs activate PPARγ in transactivation assays [20] , and PPARγ ligands were reported to be synthesized by 12/15-LOXs in an interleukin-4-dependent manner in macrophages [20, 55] . l12(S)-LOX knockout mice are viable and reproduce normally, and no adipocyte phenotype was reported [56] . Of note, l12(S)-LOX-deficient cells showed enhanced utilization of the 5-LOX pathway, indicating compensatory regulation of LOX activity [56] . The lack of an adipocyte phenotype in l12(S)-LOX-deficient mice argues that this LOX type, even though it is expressed in WAT, is dispensable for adipocyte differentiation. This conclusion is also in accordance with the absence or very low expression of l12(S)-LOX in 3T3-L1 cells. Genetic disruption of the 5-LOX gene in mice does not confer gross changes or abnormalities, and no effect on adipose tissue was reported [57] . This is consistent with our finding that 5-LOX expression is undetectable in adipose tissue and 3T3-L1 cells.
The novel eLOX-3 is the only known LOX that is expressed at significant levels in WAT, BAT and 3T3-L1 cells. Originally, eLOX-3 was reported to be expressed in the epithelia of skin, tongue and forestomach [58] . The enzymic properties of eLOX-3, including its sensitivity to LOX inhibitors, remain to be The experiments were repeated at least three times. (B) Whole cell extracts from three independent experiments were prepared on the indicated days, and the expression of eLOX-3 was analysed in parallel by Western blot analysis. Antibody recognizing TFIIB (transcription factor IIB) was used as a control for equal loading. Different lower-case letters indicate values that differ significantly (P < 0.05).
established, but it appears that eLOX-3 may utilize unconventional substrates [58, 59] . It was shown recently that eLOX-3 or 12(R)-LOX is mutated in the skin disease non-bullous congenital ichthyosiform erythroderma [60] . As mutations in either gene lead to the same phenotype, it is possible that they participate in a common metabolic pathway where the product of one enzyme is the substrate of the other.
The concentration of baicalein needed to inhibit adipocyte differentiation is comparable with that required for inhibition of conventional leucocyte-and platelet-type 12(S)-LOXs. As mentioned above, the enzymic properties of eLOX-3 and its sensitivity to baicalein remain to be established. However, our finding that eLOX-3 is a prime LOX in BAT and WAT, and the fact that eLOX-3 is the only LOX clearly detectable in 3T3-L1 cells, strongly implicate eLOX-3 in the process of adipocyte differentiation. Furthermore, forced expression of eLOX-3 modestly enhances adipocyte differentiation of 3T3-L1 cells (C. Jørgensen, R. K. Petersen, L. Madsen and K. Kristiansen, unpublished work) to a degree comparable with that seen following forced expression of ADD-1 in 3T3-L1 cells [54] , suggesting either that eLOX-3 is not limiting in this cellular system or that additional factors are needed to fully activate eLOX-3.
Our results have revealed that differentiating preadipocytes are sensitive to LOX inhibitors solely during the first 4 days of the differentiation process, and PPARγ agonists are needed only during the same period to rescue adipocyte differentiation in the presence of LOX inhibitors. The first 4 days of the differentiation process correspond to the period of mitotic clonal expansion and, interestingly, this period also coincides with the period during which 3T3-L1 cells are sensitive to inhibition by arachidonic acid and prostaglandin F 2α [48, 49] . Thus our findings show that PPAR agonists play a decisive role during the initial stages of the differentiation process, and that they may be dispensable after this period. This view is supported by the finding that the PPARγ antagonist PD068235 only inhibited adipocyte differentiation when administered during the first days of the differentiation programme [61] . Based on these observations, it would be expected that endogenous PPARγ agonists should accumulate during the early stages of the differentiation programme. In keeping with this, we demonstrate that the baicalein-sensitive production of endogenous PPARγ agonist(s) indeed increases rapidly upon induction of differentiation, reaching a maximum by days 3-4 of the differentiation process and then declining.
